SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. Atara develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom (“U.K.”). The Company’s lead product candidate is tabelecleucel (also referred to as tab-cel or EBVALLO), a ...

ATRA Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Atara Biotherapeutics, Inc. Accessibility StatementSkip Navigation What Now: You may be eligible to participate in the class action against Atara Biotherapeutics, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by May 22, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigat ...